Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4-5
|
pubmed:dateCreated |
1988-9-30
|
pubmed:abstractText |
A number of progesterone derivatives, having a 17 alpha-acetoxy group and various functions at C-3 and C-6, interact at the cardiac glycoside (CG) binding site, using [3H]ouabain in a radioligand binding assay (RBA) with membranes from dog myocardium. We now report on results of structure-activity studies concerned with modification of the A and B rings as they influence potency in the RBA. Some progesterone derivatives with 5 alpha- or 5 beta-stereochemistry show weak receptor competing activity. Among the congeners highest potency is associated with the presence of C-4 or C-4,6 unsaturation and a C-6 substituent (CH3, Cl, Br) whose importance appears to reside in its steric rather than electronic character. The C-3 function may be carbonyl, 3 beta-hydroxy or 3 beta-acetoxy when associated with C-4 or C-4,6 unsaturation. In compounds with other substituents that promote activity, C-6 alpha substitution with -CH3, -Cl, or -Br strongly enhances activity; -F, -OCH3, carbonyl, or the unsubstituted compound promotes weak binding; and -OC2H5, -OAc, -OCOOCH3, or -OH eliminates binding activity. Receptor interaction with the double bond at C-4, but not C-5, appears to be particularly important for binding. The most potent analog identified thus far is chlormadinone acetate (17 alpha-acetoxy-6-chloropregna-4,6-diene-3,20-dione), which has 1/20 the potency of ouabain in the RBA. Studies to determine optimal structural requirements for CG-receptor binding by these hormonal steroid congeners, in conjunction with appropriate biological assays, may provide insight into the nature of a putative endogenous counterpart, lead to a better understanding of the mode of action of the CG and yield CG-like compounds with superior therapeutic properties.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Digitalis Glycosides,
http://linkedlifedata.com/resource/pubmed/chemical/Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Drug,
http://linkedlifedata.com/resource/pubmed/chemical/Sodium-Potassium-Exchanging ATPase,
http://linkedlifedata.com/resource/pubmed/chemical/digitalis receptor
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0039-128X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
49
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
383-96
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3455050-Animals,
pubmed-meshheading:3455050-Digitalis Glycosides,
pubmed-meshheading:3455050-Dogs,
pubmed-meshheading:3455050-Molecular Conformation,
pubmed-meshheading:3455050-Myocardium,
pubmed-meshheading:3455050-Progesterone,
pubmed-meshheading:3455050-Radioligand Assay,
pubmed-meshheading:3455050-Receptors, Drug,
pubmed-meshheading:3455050-Sodium-Potassium-Exchanging ATPase,
pubmed-meshheading:3455050-Structure-Activity Relationship
|
pubmed:articleTitle |
Structure-activity relationships of progesterone derivatives that bind to the digitalis receptor: modifications in A and B rings.
|
pubmed:affiliation |
Faculty of Pharmacy, University of Manitoba, Winnipeg, Canada.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|